SPI Pharmaceuticals
Executive Summary
ICN subsidiary establishes a 75/25 joint venture with Galenika Pharmaceuticals, the largest drug company in Yugoslavia. SPI, which will have the controlling interest, says the new company will have consolidated sales of $370 mil., with 7,400 employees and 18 manufacturing and distribution facilities in six countries. Subject to final approval by the Yugoslavian government, the deal calls for SPI to invest $50 mil. in cash plus properties, equipment and other technological and intellectual properties, bringing the total to $360 mil. ICN Chairman Milan Panic was born in Yugoslavia and later emigrated to the U.S.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.